RECORD OF COMMERCIAL SUCCESS

Transcription

1

2

3

4

5 MULTIPLE SCLEROSIS HEMOPHILIA CD-20 THERAPIES RECORD OF COMMERCIAL SUCCESS 5 5 Note: Rituxan and Gazyva are in collaboration with Roche

6 Revenues ($B) Non-GAAP Diluted EPS ($) +18% CAGR +24% CAGR LTM* LTM* ROBUST AND GROWING BUSINESS 6 *LTM = last 12 months, Q through Q A reconciliation of our GAAP to non-gaap financial results is at the end of this presentation.

7

8 R&D TALENT NOVEL BIOLOGY MULTIPLE THERAPEUTIC MODALITIES 8

9 Therapy Target Indication Preclinical Phase 1 Phase 2 Phase 3 Neurology ZINBRYTA* Relapsing MS Secondary Progressive MS TYSABRI [ Acute Ischemic Stroke Isis SMN Rx * Spinal Muscular Atrophy BIIB037* Alzheimer's Disease Anti-LINGO Multiple Sclerosis Neublastin Neuropathic Pain CNV Trigeminal Neuralgia BAN2401* Alzheimer's Disease E2609* Alzheimer's Disease Isis DMPK Rx * Myotonic Dystrophy BIIB061 Multiple Sclerosis Anti-Tau* Alzheimer's Disease Immunology Anti-TWEAK STX-100 Anti-CD40 Ligand* Anti-BDCA2 Lupus Nephritis Idiopathic Pulmonary Fibrosis Systematic Lupus Erythematosus Systematic Lupus Erythematosus Hematology FVIII-VWF-XTEN* Zinc Finger Mediated Gene Correction* Hemophilia A [ Sickle Cell Disease Beta Thalassemia 9 *Collaboration programs Selected programs; not all inclusive Phase 3 planning underway Deal closing is contingent on HSR/regulatory approval

10 Phase 1b Alzheimer s Disease Top Line Interim Results: BIIB037 Reduced Amyloid at One Year** Acceptable Safety Profile, ARIA Observed* Dose and Time Dependent Beta Amyloid Reduction in the Brain Statistically Significant Impact on Cognition Baseline Week 54 BIIB037: POTENTIAL ALZHEIMER'S DISEASE THERAPY 10 *Amyloid Related Imaging Abnormalities. **Representative study data.

11 Phase 2 Acute Optic Neuritis Top Line Results: Acceptable Safety Profile Evidence of Proof of Biology Phase 2 Multiple Sclerosis Status: Fully Enrolled, Results in 2016 ANTI-LINGO: POTENTIAL MS REPARATIVE THERAPY 11

12

13 ~800k MS Patients ~$17B MS Market LARGE AND GROWING MARKET 13 Source: Biogen Idec data on file; global figures. Patient number represents treated patients. 13

14 ~300k Patients ~38% Market Share PORTFOLIO OF MS THERAPIES 14 Source: Biogen Idec data on file; global figures.

15 PROGRESSIVE FORMS OF MS GREAT UNMET NEEDS REMAIN IN MS REMYELINATING THERAPIES 15

16

17 >150k Hemophilia Patients ~$7B Hemophilia Market SIGNIFICANT MARKET OPPORTUNITY 17 Source: World Hemophilia Foundation 2012, global identified patients; Biogen Idec data on file; global figures. 17

18 > 60% HTCs* > 60% HTCs* STRONG PHYSICIAN ADOPTION 18 *HTCs = Hemophilia Treatment Centers; US figures. Biogen Idec data on file.

19 Strong Pipeline New Product Launches Mid & Late-Stage Programs Discovery Engine Biosimilar JV Robust Core Business ALPROLIX ELOCTATE PLEGRIDY TECFIDERA Multiple Sclerosis Hemophilia Anti-CD20 OPPORTUNITIES FOR SUSTAINABLE GROWTH 19

20 Late-Stage ZINBRYTA* Relapsing MS TYSABRI Secondary Progressive MS GAZYVA* DLBCL & NHL** SMN-Rx* Spinal Muscular Atrophy Mid-Stage TYSABRI Acute Ischemic Stroke BIIB037* Alzheimer's Disease BAN2401* Alzheimer's Disease Anti-LINGO Multiple Sclerosis CNV Trigeminal Neuralgia Anti-TWEAK Systematic Lupus Erythematosus Neublastin Neuropathic Pain STX-100 Idiopathic Pulmonary Fibrosis PROGRESSING THE PIPELINE 20 Selected programs. DLBCL = Diffuse Large B-Cell Lymphoma; NHL = Non-Hodgkin's Lymphoma. *Collaboration programs. Deal closing is contingent on HSR/regulatory approval

21

22 GAAP TO NON-GAAP RECONCILIATION Condensed Consolidated Statements of Income Operating Basis ( Unaudited, $ in millions, except per share amounts) F Y F Y F Y F Y LT M GAAP diluted EPS $ $ $ 5.76 $ $ Adjustment to net income attributable to Biogen Idec Inc. (see below) Non- GAAP diluted EPS $ 5.15 $ $ 6.53 $ $ GAAP Net Income Attributable to Biogen Idec Inc. $ 1,0 0 5 $ 1,2 3 4 $ 1,3 8 0 $ 1,8 6 2 $ 2,50 9 Amortization of intangible assets Stock option expense (Gain)/ loss on fair value remeasurement of contingent consideration associated with 2010 Panima acquisition, 2011 purchase of Dompe s noncontrolling interest and 2012 Stromedix acquisition (1) (44) In-process R&D (IPR&D) related to the 2007 Syntonix acquisition, and the 2010 IPR&D charge related to the consolidation of Knopp Weston exit costs Restructuring initiatives R&D Severance and restructuring R&D Expenses paid by Cardiokine SG&A Severance and restructuring Net income attributable to non-controlling interests: consolidation of Knopp in 2010 and expenses paid by Cardiokine in Donation to Biogen Idec Foundation (149) Income tax effect primarily related to reconciling items (116) (62) (53) (93) (144) Non- GAAP Net Income Attributable to Biogen Idec Inc. $ 1,3 15 $ 1,4 4 6 $ 1,56 7 $ 2,13 6 $ 2,8 73 Free Cash Flow Reconciliation ( unaudited, $ in millions) F Y F Y F Y F Y LT M Net cash flows provided by operating activities $ 1,625 $ 1,728 $ 1,880 $ 2,345 $ 2,878 Purchases of property, plant and equipment (Capital Expenditures) Free Cash Flow $ 1,4 52 $ 1,52 0 $ 1,6 2 5 $ 2,0 9 9 $ 3,13 7 Use of Non-GAAP Financial Measures We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered non-gaap financial measures under applicable SEC rules. We believe that the disclosure of these non-gaap financial measures provides additional insight into the ongoing economics of our business and reflects how we manage our business internally, set operational goals and forms the basis of our management incentive programs. These non-gaap financial measures are not in accordance with generally accepted accounting principles in the United States and should not be viewed in isolation or as a substitute for reported, or GAAP, net income attributable to Biogen Idec Inc. and diluted earnings per share. Our Non-GAAP net income attributable to Biogen Idec Inc. and Non- GAAP earnings per share - Diluted financial measures exclude the following items from GAAP net income attributable to Biogen Idec Inc. and diluted earnings per share: 1. Purchase accounting and merger-related adjustments. We exclude certain purchase accounting related items associated with the acquisition of businesses, assets and amounts in relation to the consolidation of variable interest entities for which we are the primary beneficiary. These adjustments include charges for in-process research and development, the amortization of certain acquired intangible assets and fair value remeasurements of our contingent consideration obligations. The exclusion of these charges provides management and investors with a supplemental measure of performance which the Company believes better reflects the underlying economics of the business. 2. Stock option expense recorded in accordance with the accounting standard for share-based payments. We believe that excluding the impact of expensing stock options better reflects the recurring economic characteristics of our business. 3. Weston Exit Costs As a result of our decision to relocate our headquarters to Cambridge, MA, we vacated a portion of our Weston, MA facility in the fourth quarter of This charge represents our remaining lease obligation for the vacated portion of our Weston facility, net of sublease income. 4. Other items. We evaluate other items on an individual basis, and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Idec Inc. Numbers may not foot due to rounding. 22